Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Detail)

v3.21.2
Stockholders' Equity - Additional Information (Detail) - $ / shares
Jun. 30, 2021
Mar. 31, 2021
Subsidiary or Equity Method Investee [Line Items]    
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (in shares) 10,000,000 10,000,000
Common share, authorized (in shares) 500,000,000 500,000,000
Common share, issued (in shares) 97,977,595 97,971,243
Common share, outstanding (in shares) 97,977,595 97,971,243
Series A  preferred stock    
Subsidiary or Equity Method Investee [Line Items]    
Preferred stock, issued (in shares) 10,000 10,000
Preferred stock, outstanding (in shares) 10,000 10,000
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Liquidation amount per share (in dollars per share) $ 0.01  
Preferred stock, authorized (in shares) 10,000 10,000
Series A  preferred stock | Maximum    
Subsidiary or Equity Method Investee [Line Items]    
Percentage of voting power of outstanding shares 25.00%  
Roivant Sciences Ltd. | Series A  preferred stock    
Subsidiary or Equity Method Investee [Line Items]    
Preferred stock, issued (in shares) 10,000  
Preferred stock, outstanding (in shares) 10,000  
Preferred stock, par value (in dollars per share) $ 0.0001  
Preferred Stock    
Subsidiary or Equity Method Investee [Line Items]    
Preferred stock, issued (in shares) 0  
Preferred stock, outstanding (in shares) 0  
Preferred stock, authorized (in shares) 10,010,000  
Common stock    
Subsidiary or Equity Method Investee [Line Items]    
Common share, authorized (in shares) 500,000,000  
Common stock, par value (in dollars per share) $ 0.0001  
Common share, issued (in shares) 97,977,595  
Common share, outstanding (in shares) 97,977,595